Atsena Therapeutics

Atsena Therapeutics is a leading biotechnology company focused on developing innovative gene therapies to combat inherited retinal diseases and prevent blindness. Atsena Therapeutics is dedicated to creating best-in-class treatments that address the unmet needs of patients facing vision loss.

With a strong emphasis on research and development, Atsena Therapeutics is advancing its lead program, ATSN-201, through an ongoing Phase 1/2/3 clinical trial for X-linked retinoschisis (XLRS). Additionally, ATSN-101, an investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), has shown promising results in a Phase 1/2 trial and is progressing toward a global pivotal trial in collaboration with Nippon Shinyaku Co., Ltd. Atsena Therapeutics is committed to pushing the boundaries of ocular gene therapy.

Driven by cutting-edge adeno-associated virus (AAV) technology, Atsena Therapeutics is uniquely positioned to tackle the challenges presented by inherited retinal diseases. The company's pipeline reflects its commitment to delivering transformative therapies to patients worldwide. We invite the management team at Atsena Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.